Teva Neuroscience, Inc.

Quick facts

Marketed products

• Rasagiline mesylate plus Mirapex · Neurology
  This combination pairs a monoamine oxidase B inhibitor with a dopamine agonist to enhance dopaminergic signaling in the brain for Parkinson's disease management.
• Rasagiline mesylate with Levodopa · Neurology
  Rasagiline is a monoamine oxidase B (MAO-B) inhibitor that increases dopamine levels in the brain, while levodopa is converted to dopamine to replace depleted neurotransmitter in Parkinson's disease.
• Rasagiline mesylate with Requip · Neurology
  Rasagiline is a monoamine oxidase B (MAO-B) inhibitor that increases dopamine levels in the brain, while ropinirole (Requip) is a dopamine D2/D3 receptor agonist, together enhancing dopaminergic signaling for Parkinson's disease management.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Teva Neuroscience, Inc. portfolio CI brief
• Teva Neuroscience, Inc. pipeline updates RSS